Wakefulness

Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)

Retrieved on: 
Tuesday, September 20, 2022
Cataplexy, Safety, COVID-19, CNTA, Risk, MD, Drug, Drug design, U.S. Securities and Exchange Commission, Narcolepsy, IND, Wakefulness, Company, Sleep, Poster, OX1R, Industry, Cryogenic electron microscopy, Maintenance, WT, Head, Patient, NT2, Program, Clinical trial, OX2R, Annual report, Nasdaq, Omicron, Doctor of Philosophy, NT1, Research, Conference, GLOBE, SEC, Awareness, Disease, Research and development, Pharmaceutical industry, Delta

BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that non-clinical data from its oral orexin receptor 2 (OX2R) agonist discovery pipeline have been accepted for poster presentation at the 26th Conference of the European Sleep Research Society meeting (Sleep Europe 2022) being held on September 27-30, 2022, in Athens, Greece. Centessa’s OX2R agonists are designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 (NT1), with potential expansion into narcolepsy type 2 (NT2), and other sleep disorders.

Key Points: 
  • These novel OX2R agonist compounds showed high potency in activating recombinant human and endogenous mouse OX2Rs, with more than a thousand-fold selectivity for OX2R compared to OX1R.
  • Our innovative pipeline is both a testament to their expertise and strong validation of our approach to structure-based drug design.
  • We are encouraged by the non-clinical data and are rapidly progressing several potentially best-in-class oral small-molecule OX2R agonists through our discovery pipeline.
  • We are excited to showcase some of our small-molecule OX2R agonist discovery pipeline and share these data at Sleep Europe 2022, said Mario Alberto Accardi, PhD, Head, Centessa Orexin Program.

Tris Pharma Announces Development of a Very Low Sodium and Once-Nightly Oxybate Formulation

Retrieved on: 
Wednesday, July 27, 2022
Ketan, Somnolence, Time, Absorption, Multiple sclerosis, Hess, EDS, Jazz Pharmaceuticals, Trial of the century, Narcolepsy, Classification, List of Hindawi academic journals, Hallucination, Incidence, GM, Kingsley v. Hendrickson, CNS, Spasticity, Knowledge Organization (journal), Excessive daytime sleepiness, Epidemiology, Cataplexy, Sleep, ADHD, Wakefulness, Patient, Sodium, Cerebral palsy, Pain, Emotion, Hypertension, Heart failure, Sleep paralysis, Sodium oxybate, Prevalence, Neurological disorder, Pharmaceutical industry, Tris

The Tris oxybate formulation is believed to provide an advantage over approved therapies by utilizing Tris's proprietary LiquiXR technology platform and our newly developed RaftWorks design to provide a unique oxybate formulation offering both once-nightly dosing, and very low sodium content.

Key Points: 
  • The Tris oxybate formulation is believed to provide an advantage over approved therapies by utilizing Tris's proprietary LiquiXR technology platform and our newly developed RaftWorks design to provide a unique oxybate formulation offering both once-nightly dosing, and very low sodium content.
  • The Tris oxybate formulation seeks to improve on existing therapies by providing convenient once per night dosing, and significantly reduced sodium content such that it will contain less than 100 mg of sodium per 9.0 gm of maximum sodium oxybate equivalent dose.
  • Based on the significant potential advantage the Tris oxybate formulation could provide over existing available therapies, Tris is pursuing an Orphan Drug Designation for its unique oxybate formulation.
  • The Tris oxybate product achieved its clinical objectives by combining two distinct proprietary Tris technologies: the LiquiXR platform, and the newly developed RaftWorks design.

Dr. Steven Gundry’s Gundry MD Energy Renew Celebrates 1400+ Positive Reviews Across Multiple Platforms

Retrieved on: 
Wednesday, July 20, 2022
Olive, Digestion, Vitality, Skin, GLOBE, Paradox, Instagram, Food, Polyphenol, Goop, Research, Health, Nutrient, Metabolism, Steven Gundry, Cell, Weight gain, Wakefulness, Disease, MD, Weight loss, Heart, LOS, Center, Food and Drug Administration, Dietary supplement, Medical device, Facebook, The New York Times

LOS ANGELES, July 20, 2022 (GLOBE NEWSWIRE) -- Gundry MDTM Energy Renew now has over 1400 positive reviews across multiple platforms. This revolutionary dietary supplement was designed by Dr. Steven Gundry, medical researcher and world-renowned heart surgeon, to help support a youthful heart, energy, and vitality. Naturally, we all age - and as a result we can experience a decrease in energy levels meaning our body is "slowing down" internally. This can result in multiple problems such as a slower metabolism, weight gain, and effects on your overall health. Gundry MD Energy Renew helps you combat these issues by reenergizing your body and supporting your metabolism.†*

Key Points: 
  • Gundry MD Energy Renew helps you combat these issues by reenergizing your body and supporting your metabolism.
  • *
    Gundry MD Energy Renew is passionfruit and hibiscus-flavored dietary supplement that was formulated to help your body create natural energy by supporting the cells in your body.
  • Gundry MD Energy Renew also helps your body fight free radicals which can accelerate our age - and further decrease energy.
  • Re-energization is just one of the benefits of Gundry MD Energy Renew, others include an improvement in the appearance of skin and metabolism support.

Idorsia Announces World Champion Skier, Philanthropist and Entrepreneur Lindsey Vonn as Patient Ambassador for QUVIVIQ™ (daridorexant), a Once Nightly Treatment for Insomnia

Retrieved on: 
Tuesday, July 19, 2022
Sleep apnea, Thought, Adult, Alertness, Mental health, Lung, Research, Facebook, United States Census Bureau, Sleep hygiene, Patient, Lists of diseases, Headache, Vitamin, Pain, Wakefulness, Academy of Family Physicians of India, Falling, Sleep, Depression, Cognitive behavioral therapy, Population, Tell, Full, Twitter, General manager, Hyperkinesia, Goal, Exercise, Lindsey, Sleep disorder, Cataplexy, Brain, CIV, Knee, PI, Muscle weakness, Medication, Sex, Multimedia, Tablet, Medicine, Instagram, Complex, Prevalence, Health, Conditional sentence, Hallucination, Partnership, Sleep paralysis, FDA, Somnolence, Diet, Suicide, Awareness, Pharmaceutical industry, Dietary supplement, Liquor, Residential care, Mail order, Risk management, Incorporation (business), Insomnia

RADNOR, Pa., July 19, 2022 /PRNewswire/ -- Idorsia Pharmaceuticals, U.S. Inc, today announced its partnership with Lindsey Vonn, world champion skier, philanthropist, entrepreneur and insomnia patient as an ambassador for QUVIVIQ (daridorexant) CIV.

Key Points: 
  • RADNOR, Pa., July 19, 2022 /PRNewswire/ -- Idorsia Pharmaceuticals, U.S. Inc, today announced its partnership with Lindsey Vonn, world champion skier, philanthropist, entrepreneur and insomnia patient as an ambassador for QUVIVIQ (daridorexant) CIV.
  • I talked with my doctor and was prescribed QUVIVIQ, a new prescription treatment for adults with insomnia," says Vonn.
  • Adults struggling with sleep should speak with their doctor to see if QUVIVIQ is the right treatment option for them.
  • Vonn's doctor prescribed her QUVIVIQ and after taking QUVIVIQ nightly, she started to notice a difference in her sleep.

Sleep Number Unveils New Research from Its 360® Smart Bed on Temperature Sensing and Daytime Alertness

Retrieved on: 
Wednesday, June 8, 2022
Retail, Home Goods, Science, Research, Science, Sleep Number, VP, Circadian rhythm, LLC, Alertness, Temperature, Abdomen, Pressure, Annual report, Observational study, Skin temperature, News, Associated, Security (finance), Alternative, Wakefulness, Psychiatry, U.S. Securities and Exchange Commission, Somnolence, Multimedia, University, Torso, FDA, Sleep, Memory, Bed, PSG, Technology, Secondary research, Health, Efficiency, Newsroom, TPM, University of Pittsburgh, SEC, Skin, Individual, Pharmaceutical industry, Research

To date, Sleep Number has leveraged and learned from over 15 billion hours of sleep data gathered from over 1.8 billion real-world sleep sessions.

Key Points: 
  • To date, Sleep Number has leveraged and learned from over 15 billion hours of sleep data gathered from over 1.8 billion real-world sleep sessions.
  • Sleep Numbers study sought to unobtrusively estimate distal skin temperature during sleep using a temperature sensor array on a bed.
  • Sleep Number compared their distal skin temperature data to that of a research-grade, FDA-approved smart watch and then used the sleep data from the 360 smart bed to build predictive models estimating distal skin temperature.
  • Sleep Number 360 smart bed sleepers rated their subjective alertness on a scale from one to 10 through the SleepIQ technology app.

Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Retrieved on: 
Monday, May 9, 2022
Jazz Pharmaceuticals, Narcolepsy, Department, Somnolence, Headache, CPAP, Appetite, Insurance, University, EMA, Press release, EDS, NASDAQ, Disability, European Medicines Agency, Obstructive sleep apnea, GLOBE, CNS, Excessive daytime sleepiness, OSA, Food, Research, Depression, Medical school, Epworth Sleepiness Scale, Â, Patient, Medical University of South Carolina, Neurology, FDA, Incidence, Airway obstruction, Anxiety, FCCP, Regulation of tobacco by the U.S. Food and Drug Administration, Dopamine, Adult, MAOI, Quality of life, Continuous positive airway pressure, Wakefulness, Psychiatry, Central nervous system, Nausea, Risk, Acquisition, Therapy, Pharmaceutical industry, Solriamfetol, Neuroscience, Medicine, MD

Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

Key Points: 
  • Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
  • The effect of excessive daytime sleepiness on individuals with narcolepsy and obstructive sleep apnea includes functional impairment, reduced quality of life, and increased risk for occupational and motor vehicle accidents.
  • Axsome recognizes the importance of providing patients with EDS associated with narcolepsy and OSA affordable access to Sunosi.
  • Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Retrieved on: 
Monday, May 9, 2022
Accident, Jazz Pharmaceuticals, Narcolepsy, Department, Somnolence, Headache, CPAP, Appetite, Insurance, University, EMA, Press release, EDS, NASDAQ, Disability, European Medicines Agency, Obstructive sleep apnea, CNS, Excessive daytime sleepiness, OSA, Food, Research, Depression, Medical school, Epworth Sleepiness Scale, Patient, Medical University of South Carolina, Neurology, FDA, Incidence, Airway obstruction, Anxiety, FCCP, Regulation of tobacco by the U.S. Food and Drug Administration, Dopamine, Adult, MAOI, Quality of life, Continuous positive airway pressure, Wakefulness, Psychiatry, Central nervous system, Nausea, Risk, Acquisition, Therapy, Pharmaceutical industry, Solriamfetol, Neuroscience, Medicine, MD

Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

Key Points: 
  • Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
  • The effect of excessive daytime sleepiness on individuals with narcolepsy and obstructive sleep apnea includes functional impairment, reduced quality of life, and increased risk for occupational and motor vehicle accidents."
  • Axsome recognizes the importance of providing patients with EDS associated with narcolepsy and OSA affordable access to Sunosi.
  • Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist

Retrieved on: 
Wednesday, May 4, 2022
Sleep, Neuroscience, Jazz Pharmaceuticals, Narcolepsy, Psychiatry, Twitter, Health, EDS, Pharmacokinetics, Sleep paralysis, NASDAQ, Idiopathic hypersomnia, Excessive daytime sleepiness, Safety, Drug discovery, Patient, Commission, Risk, Orexin, Annual report, DNS, U.S. Securities and Exchange Commission, Sleep disorder, Neurology, Wakefulness, Cataplexy, Research, Head, Neuropeptide, Pharmaceutical industry, TSE, Jazz

DUBLIN and OSAKA, Japan, May 4, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) today announced that the companies have entered into an exclusive licensing agreement under which Jazz has acquired development and commercialization rights in the United States, Europe and other territories for Sumitomo Pharma's investigational DSP-0187, a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders. Jazz has designated this molecule JZP441.

Key Points: 
  • Sumitomo Pharma initiated a Phase 1 trial in Japan of DSP-0187 in November 2021 to evaluate safety, tolerability and pharmacokinetics in healthy volunteers.
  • "Orexin agonism is an exciting area of sleep disorder research and an approach that may be complementary to oxybate therapy.
  • "DSP-0187 is a potent, highly selective oral orexin-2 receptor agonist, which is a novel small molecule compound originally created by Sumitomo Pharma by utilizing our advanced expertise in drug discovery for central nervous system disorders.
  • DSP-0187 is a potent, highly selective orexin-2 receptor agonist designed to activate orexin signaling.

Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 2, 2022
AXS-05, CRL, Narcolepsy, Chemistry, Excessive daytime sleepiness, OSA, Safety, Depression, MDD, Fibromyalgia, Migraine, Central nervous system, Disease, Jazz Pharmaceuticals, AD, SYMPHONY, Smoking cessation, NASDAQ, Company, DCC, Patient, Clinical trial, FDA, New Drug Application, Breakthrough therapy, Research, Priority review, Therapy, ACCORD, EDS, Obstructive sleep apnea, NDA, Physician, Endpoint security, Central nervous system disease, Agitation, Dopamine, MD, R, Lists of diseases, CMC, Growth, Acquisition, CNS, NMDA, GEMINI, Food and Drug Administration, Food, Review, Webcast, Adult, Wakefulness, ID, G&A, Reboxetine, ASCEND, Pharmaceutical industry, Risk management, Bank, Online gambling, Solriamfetol, Alzheimer's disease, COVID-19

NEW YORK, May 2, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • NEW YORK, May 2, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2022.
  • Based on this interaction, the Company anticipates potential FDA action on the NDA in the second quarter of 2022.
  • The Company is evaluating the design of the study and will provide an update following consultation with the FDA.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss first quarter 2022 financial results as well as to provide a corporate update.

Mom's protective behaviors run deep in the brain, new CSHL research finds

Retrieved on: 
Thursday, March 24, 2022
Cell, Locus coeruleus, Laboratory, NA, Cold, Memory, Multimedia, Neuroscience, Mouse, Cold Spring Harbor Laboratory, SPRING, Sleep, Cancer, Wakefulness, Shea, Autism, LC, Nobel Prize, Biomedical Research, Arousal, Vertebrate, Brain, Disorder, Student, Hypothermia, Neuron, Anxiety, Female, Depression, Education, CSHL, Medical imaging

Neuroscientists at Cold Spring Harbor Laboratory (CSHL) now report this resemblance applies in more ways than one.

Key Points: 
  • Neuroscientists at Cold Spring Harbor Laboratory (CSHL) now report this resemblance applies in more ways than one.
  • "We study pup retrieval because it's very reliable and it's done the same way every time," says Shea.
  • The recordings show LC neurons spike in activity at the exact moment a mom touches a pup to retrieve it.
  • Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology.